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Gastric cancer cells often show altered Ras signaling, though the
underlying molecular mechanism is not fully understood. We ex-
amined the expression proﬁle of eight ras-association domain
family (RASSF) genes plus MST1/2 and found that RASSF2A is
the most frequently downregulated in gastric cancer. RASSF2A
wascompletelysilencedin6of10gastriccancercelllinesasaresult
of promoter methylation, and expression was restored by treating
the cells with 5-aza-2#-deoxycytidine. Introduction of RASSF2A
into non-expressing cell lines suppressed colony formation and
induced apoptosis. These effects were associated with the cyto-
plasmic localization of RASSF2A and morphological changes to
the cells. Complementary DNA microarray analysis revealed that
RASSF2A suppresses the expression of inﬂammatory cytokines,
which may inturnsuppressangiogenesis and invasion.In primary
gastric cancers, aberrant methylation of RASSF2A was detected
in 23 of 78 (29.5%) cases, and methylation correlated signiﬁcantly
with an absence of the lymphatic invasion, absence of venous in-
vasion, absence of lymph node metastasis, less advanced stages,
Epstein–Barr virus, absence of p53 mutations and the presence of
the CpG island methylator phenotype-high. These results suggest
that epigenetic inactivation of RASSF2A is required for tumori-
genesis in a subset of gastric cancers.
Introduction
Gastric cancer is one of the most common of human neoplasias (1). It
often arises through the accumulation of multiple genetic changes,
including mutation of APC, K-ras and p53, but the frequencies of
oncogene and tumor suppressor gene mutation in gastric cancer are
relatively low, as compared those seen in colorectal cancer (2,3). On
the other hand, recent studies have shown that epigenetic alterations
(e.g. DNA methylation) play a key role in silencing such cancer-
related genes such as p16INK4A, CHFR, E-cadherin, 14-3-3r and
DAP-kinase (4–7), and genome-wide methylation screening has iden-
tiﬁed a number of genes inactivated by DNA methylation in gastric
cancer (8,9). In that regard, Helicobacter pylori infection, a potent
gastric carcinogenic factor, reportedly induces methylation of various
genes in the gastric mucosa (10). Still, the precise role of DNA meth-
ylation in gastric cancer remains unclear.
Ras proteins play essential roles in controlling the activity of several
important signaling pathways that regulate cellular proliferation, migra-
tion and apoptosis (11), and alteration of Ras signaling can lead to
tumorigenesis. In fact, mutations of K-ras and BRAF have been ob-
served in a number of human neoplasias (12,13), though their mutation
rarely occurs in gastric cancer (14). Notably, activated forms of Ras also
caninduce senescenceand apoptosis, indicating the presenceof negative
effectors regulated by Ras. Such effectors are commonly the products of
RASSF family genes, and contain a Ras association (RA) domain. Al-
terations of these negative effectors of Ras also can play a role in
tumorigenesis. For instance, epigenetic inactivation of RASSF1, a candi-
date tumor suppressor gene on chromosome 3p21, has been well char-
acterized in a wide variety of tumors (15,16). So far, six members of the
RASSF gene family, RASSF1A, RASSF2A, RASSF4, RASSF5/NORE1,
RASSF6 and RASSF8, have been shown to be inactivated or downregu-
lated in human neoplasias (15–25). Of those, RASSF2A is frequently
inactivated in colorectal, gastric, lung and nasopharyngeal cancers, al-
though the molecular mechanisms by which RASSF2A functions as
a tumor suppressor remains unknown (17,20,22,23,25).
In addition, MST1 and MST2 encode serine/threonine kinases that
associate with RASSF family proteins (e.g. RASSF1 and RASSF5/
NORE1) (26,27), and they are epigenetically inactivated in soft tissue
sarcoma (28). The role of the RASSF/MST pathway in gastric cancer
is not known, however.
In the present study, we examined the epigenetic alteration of
RASSF family genes together with MST1/2 in a panel of gastric cancer
cell lines. We found that, of those, RASSF2A is the most frequently
downregulated in gastric cancer. Introduction of RASSF2A into gas-
tric cancer cells that do not otherwise express the gene signiﬁcantly
diminished colony formation and induced apoptosis. Induction of
apoptosis by RASSF2A is associated with morphological changes
and cytoplasmic localization of RASSF2A. Taken together, these
ﬁndings suggest that epigenetic inactivation of RASSF2A plays
a key role in tumorigenesis in gastric cancer.
Materials and methods
Cell lines and specimens
Twelvegastriccancercelllinesand78primarygastriccancerspecimenswereused
in this study. Among the cell lines, eight were obtained from American Type
Culture Collection, Tokyo, Japanor JapaneseCollection ofResearch Bioresources
Tokyo, Japan, whereas two (HSC44 and SH101) were kindly provided by
Dr K.Yanagihara at the National Cancer Center Research Institute and were de-
scribed previously (29,30). The 78 gastric cancer specimens were described pre-
viously (8,31). Written informed consent was obtained from every patient and
approved by theInstitutionalReviewBoard.DNAwaspreparedusingthestandard
phenol–chloroform method. Total RNA was isolated using Trizol (Invitrogen).
Reverse transcription–polymerase chain reaction
Five micrograms of total RNA were reverse transcribed using Superscript III
reverse transcriptase (Invitrogen, Carlsbad, CA). Polymerase chain reaction
(PCR) was carried out using primers speciﬁc for RASSF2 exon 1A and exon
1B (supplementary Table 1 is available at Carcinogenesis Online). To analyze
Abbreviations: 5-aza-dC, 5-aza-2#-deoxycytidine; CIMP, CpG island meth-
ylator phenotype; NLS, nuclear localization signal; PCR, polymerase chain
reaction; RA, Ras association.
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were incubated for 72 h with 2 lM 5-aza-2#-deoxycytidine (5-aza-dC) (Sigma,
St Louis, MO). For quantitative real-time PCR, reactions were carried out
using a 7900 Sequence Detection System (Applied Biosystems, Foster City,
CA). The primers and probes for each gene are shown in supplementary
Materials and Methods (available at Carcinogenesis Online). The relative
levels of RASSF2A expression were quantiﬁed using the DCt value, which
yields a ratio of the expression of a target gene to that of a housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Bisulﬁte sequencing and pyrosequencing
Sodium bisulﬁte treatment was performed as described previously (32). The
primer sequences and PCR parameters used are shown in supplementary Table 1
(available at Carcinogenesis Online). PCR products were cloned into pCR4.0
vector using a TOPO-TA Cloning Kit (Invitrogen). The sequencing reaction
was carried out using a BigDye terminator cycle sequencing kit (PerkinElmer
Biosystems, Foster city, CA), and sequencing was carried out using an ABI
PRISM 3100 sequencer according to the manufacturer’s guidelines (Applied
Biosystems). Pyrosequencing was carried out as described previously (33,34),
and the details are shown in supplementary Materials and Methods (available
at Carcinogenesis Online).
Colony formation assay
An expression plasmid, pcDNA-RASSF2A, containing the entire coding region
of human RASSF2A was constructed using the expression vector
pcDNA3.1(þ), which harbors a gene conferring geneticin resistance. Cells at
25% conﬂuence in 10 cm dishes were transfected with 5 lg of one of three
expression plasmids (pcDNA-RASSF2A, pcDNA-RASSF2-DRA or pcDNA3.1
control vector) using Nucleofector (Amaxa, Berlin, Germany) as described pre-
viously (17). Twenty-four hours after transfection, the cells were split 1:10 and
grown for 14 days in the presence of G418 (Gibco BRL, Grand Island, NY)
(0.3–0.6 mg/ml). The cells were then ﬁxed and stained with Giemsa, and the
number of colonies was scored. Experiments were performed in triplicate and
repeated on two independent occasions.
Construction of adenoviral vectors and ﬂow cytometry analysis
Thegeneration, puriﬁcationandinfectionproceduresusedwiththe replication-
deﬁcient recombinant adenovirus were described previously (35,36). For ﬂow
cytometric analysis, 1   106 cells were infected with an adenoviral vector
containing RASSF2A (aa 1–326), RASSF2A-DN (aa 164–326), RASSF2A-
DRA (aa 1–163), RASSF2A-DNLS (aa 1–149/168–326) or green ﬂuorescent
protein.Thecells werethenincubatedfor24,48 or72h, trypsinized,ﬁxedwith
methanol, rehydrated with phosphate-buffered saline, treated with 2 mg/ml
RNase for 30 min at 37C and stained in 50 lg/ml propidium iodide solution.
Fluorescence-activated cell sorting analysis was carried out using a Becton
Dickinson FACScan ﬂow cytometer (Braintree, MA).
Immunocytochemistry
Cells (1   104) were seeded on glass coverslips, infected with an adenoviral
vector and ﬁxed with 4% paraformaldehyde. Immunoﬂuorescence analysis was
carried out using mouse anti-Flag antibody and Alexa 488. For paxillin staining,
the cells were incubated for 1 h with 0.1 lg/mlrhodamine-conjugatedphalloidin
(BD Bioscience, San Jose, CA). For Flag-RASSF2A staining, cells were incu-
bated ﬁrst with mouse anti-Flag monoclonal antibody (Sigma) and then with
Alexa 488 goat anti-mouse antibody (Molecular Probes, Eugene, OR). Once
labeled, the cells were examined under an Olympus IX71 ﬂuorescence micro-
scope. Nuclei were counterstained with 4#,6-diamidino-2-phenylindole.
Results
Epigenetic inactivation of RASSF family genes in gastric cancer
cell lines
To determine the expression proﬁle of negative effectors of Ras in
gastric cancer, we examined the expression status of eight RASSF
family genes plus MST1 and MST2 in a panel of gastric cancer cell
lines. Of the 10 genes analyzed, the expression of RASSF2 was the
most frequently downregulated in gastric cancer (Figure 1A). As a re-
sult of different transcription start sites, RASSF2 has four major tran-
scription variants: RASSF2A variant 1, RASSF2A variant 2, RASSF2B
and RASSF2C. Analysis of the expression of each of these four iso-
forms revealed that both RASSF2A variants are expressed in all the
normal tissues we tested (Figure 1B, upper panel). In contrast, their
expression was lost in six gastric cancer cell lines (Figure 1B, lower
panel) and, in MKN28 cells, expression of variant 1 was readily de-
tected, but expression of variant 2 was very weak. Treating the gastric
cancer cell lines with a methyltransferase inhibitor restored expression
of the RASSF2Avariants, indicating a role for DNA methylation in the
silencingofRASSF2Aexpression(Figure1C).Moreover,whenwenext
examined RASSF2 expression after treating cells with a low dose of
5-aza-dC and/or Trichostatin A(TSA), we found that treating HCC44
cells with 300 nM TSA or 0.2 lM 5-aza-dC had little effect on gene
expression, but TSA plus 5-aza-dC acted synergistically to restore
RASSF2A expression, which suggests the involvement of histone de-
acetylation in the gene’s silencing (Figure 1D). Very little, if any, ex-
pression of RASSF2B and RASSF2C was detected (data not shown).
Aberrant methylation of RASSF2A in gastric cancer cell lines
To assess the role of DNA methylation in the silencing of RASSF2A in
more detail, we used bisulﬁte sequencing to examine 37 CpG sites
located around exons 1A and 1B of RASSF2 in our panel of gastric
cancer cell lines (Figure 1D). We detected high levels of methylation
of exon 1A in JRSTand KatoIII cells, which were consistent with the
expression analysis. MKN28 cells showed high levels of methylation
of exon 1B but not 1A, which are consistent with their expression of
RASSF2Avariant 1 and only a minimal amount of RASSF2Avariant 2.
Only sparse methylation was detected in MKN7, MKN74 and SH101
cells, which expressed the gene.
Effect of RASSF2A on cell growth and apoptosis in gastric
cancer cells
To determine whether RASSF2A exerts an antiproliferative effect, we
carried out a set of colony formation assays. Schematic representa-
tions of the various RASSF2 deletion constructs are shown in supple-
mentary Figure 1 (available at Carcinogenesis Online). We found that
introduction of RASSF2A into JRST and HSC44 cells resulted in
a signiﬁcant reduction of colony formation (Figure 2A and B). In
contrast, a mutant form of RASSF2A that lacked the RA domain
(DRA) was less able to suppress growth, indicating a role for the
RA domain in suppression of cell growth. To investigate the role of
RASSF2A-mediated inhibition of growth in more detail, we intro-
duced Ad-RASSF2A into gastric cancer cell lines in which the gene
was silenced. Transformation by Ad-RASSF2A induced apoptosis in
JRSTand SNU1 cells, which otherwise did not express RASSF2A,b u t
did not induce apoptosis in cells that did express RASSF2A.
During the course of the experiments, we repeatedly noticed that
RASSF2A transformants exhibited a round morphology, suggesting
that RASSF2A expression leads to the inhibition Ras and, in turn,
inhibition of focal adhesion and stress ﬁber formation and activation
of paxillin. To test that idea, we used immunocytochemistry to exam-
ine paxillin expression (Figure 3A) and conﬁrmed that the RASSF2A-
induced round morphology was caused by the absence of stress ﬁbers.
We then examined whether these morphological changes induce
apoptosis or whether it is apoptosis that induces the observed mor-
phological changes. After transformation with Ad-RASSF2A, the
numbers of ﬂoating cells increased, as did the incidence of apoptosis
(Figure 3B). When we treated the cells with a non-speciﬁc caspase
inhibitor, the number of ﬂoating cells increased, but the number of
apoptotic cells decreased. This suggests that RASSF2A expression
alters the morphology of cells, which leads ﬁrst to a loss of adhesion
and then to caspase-dependent apoptosis.
We next analyzed its protein motifs and found that RASSF2A
carries three putative nuclear localization signals (NLSs) in the
N-terminal region ofits RAdomain(NLS, RRRGNVRTPSDQRRIRR;
start position, 150). Although RASSF2A expressed in JRST cells was
localized in both the nucleus and cytoplasm, RASSF2A lacking the
NLS (RASSF2A-DNLS) was found only in the cytoplasm, indicating its
NLS is a key determinant of the intracellular distribution of RASSF2A
(Figure 4A). Interestingly, when introduced into cells, RASSF2A-
DNLS exerted a strong proapoptotic effect (Figure 4B).
Identiﬁcation of genes induced by RASSF2A
To learn more about the molecular pathway via which RASSF2A
suppresses cell growth and induces apoptosis, we used
RASSF2A in gastric cancer
1313a complementary DNA microarray to determine the genes induced or
suppressed by RASSF2A. We found that, in JRST cells, overexpres-
sion of RASSF2A led to upregulation of 39 genes and downregulation
of 31 genes (supplementary Table 2 is available at Carcinogenesis
Online). Gene ontology analysis revealed that genes involved in im-
mune responses, viral function, cell-to-cell signaling and infection
were all signiﬁcantly enriched among RASSF2A inducible/downre-
gulated genes (supplementary Table 3 is available at Carcinogenesis
Online). Ingenuity pathway analysis also revealed that genes regulated
via the nuclear factor-jB pathway were frequently downregulated by
RASSF2A (supplementary Figure 2 is available at Carcinogenesis
Online). To conﬁrm the results of the microarray analysis, we per-
formed real-time PCR to examine the expression of several putative
RASSF2A target genes (supplementary Figure 3A is available at
Carcinogenesis Online). The levels of IL-8, LCN2, CXCL2, CXCL3,
CXCL5 and CCL20 expression were all reduced in cells transformed
by Ad-RASSF2A. Conversely,expression ofCXCL2 and CXCL5 was
upregulated in cells where RASSF2A expression was knocked down
using speciﬁc small interfering RNA (siRASSF2) (supplementary
Figure 3B is available at Carcinogenesis Online).
Fig. 1. Epigenetic inactivation of RASSF2A in gastric cancer cell lines. (A)E x p r e s s i o np r o ﬁ l eo fRASSF1–8, MST1 and MST2 in gastric cancer cell lines.
The heat map shows the expression proﬁles in normal colon, normal stomach and three cancer cell lines. Levels of expression are normalized to GAPDH.
(B) Expression of RASSF2A variant 1 (Ex1A) and variant 2 (Ex1B) in gastric cancer cell lines. Reverse transcription–PCR analysis was performed using
primers that speciﬁcally amplify two isoforms of RASSF2. The cell lines examined were shown on the top. Expression of GAPDH was examined to conﬁrm the
integrity of RNA. (C)R e s t o r a t i o no fRASSF2 expression by treating cells with 1.0 lM 5-aza-dC. (D) Restoration of RASSF2 expression using 5-aza-dC
and TSA. HSC44 cells were treated with mock, 300 nM TSA for 18 h, 0.2 lM 5-aza-dC for 72 h or 0.2 lM 5-aza-dC for 72 h followed by 300 nM of TSA for
18 h (A þ T). (E)A n a l y s i so fRASSF2A methylation. Schematic representation of the RASSF2A CpG island is shown on the top. Arrows indicate the
transcription start sites. Bisulﬁte sequencing analysis of RASSF2Awas carried out using DNA from three gastric cancer cell lines that express both variant 1 and
variant 2 (MKN7, MKN74 and SH101), six gastric cancer cell lines that do not express either variant (JRST, KatoIII, SNU1, SNU638, NUGC3 and HSC44) and
MKN28 cells, which express variant 1 but only a low level of variant 2. Open circles indicate the unmethylated CpG sites; ﬁlled circles indicate the methylated
CpG sites.
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1314Clinicopathological features of gastric cancers with or without
methylation of RASSF2A
Finally, we used pyrosequencing to examine the methylation status of
RASSF2A in a set of primary gastric cancer specimens (Figure 5A).
Primers and probe sets were designed to detect methylation in the
region around the transcription start sites in exons 1A and 1B. We
used minimum of 10% methylation as a cutoff for methylation pos-
itivity, as methylation in normal tissue is always ,10%. The degreeof
methylation in 78 primary gastric cancers, including 23 cases in
which samples of adjacent normal tissue were also collected, are
shown in supplementary Figure 4 (available at Carcinogenesis On-
line). Methylation of exon 1A was detected in 23 of the 78 (29.5%)
tumors, whereas methylation of exon 1B was detected in 20 (25.6%)
of the tumors. Good quality RNA was obtained from 18 specimens
(10 with no methylation of RASSF2-Ex1A or RASSF2-Ex1B; 8 with
methylation of both RASSF2-Ex1A and RASSF2-Ex1B), which we
used to examine the correlation between DNA methylation and
RASSF2A expression. We found that the level of RASSF2A expression
was signiﬁcantly lower in tumors with methylation than in tumors with-
out methylation (P , 0.01, Fisher’s exact test, two sided, Figure 5B).
The methylation proﬁles, mutations of p53/K-ras and the epstein-barr
virus (EBV) status of the 78 gastric tumors studied are summarized in
Figure 5C (31). There was signiﬁcant association between methyla-
tion of RASSF2A and an absence of lymphatic invasion (P 5 0.007),
absence of venous invasion (P 5 0.008), absence of lymph node me-
tastasis (P 5 0.029), less advanced stage (P 5 0.005), EBV (P ,
0.001), absence of p53 mutations (P 5 0.002) and the presence of
CpG island methylator phenotype (CIMP)-high (P , 0.001). There
were signiﬁcant correlations between methylation of RASSF1 andRASS-
F2A-Ex1A (P , 0.001), RASSF1 and RASSF2A-Ex1B (P , 0.001)
and RASSF2A-Ex1A and RASSF2A-Ex1B (P , 0.001) (supplementary
Table 4 is available at Carcinogenesis Online). Moreover, when we then
examined the correlation between methylation of RASSF1/RASSF2A
and 12 other cancer-related genes previously examined for methylation
(31), we found signiﬁcant correlations between methylation of RASSF1
and eight genes, between methylation of RASSF2A-Ex1A and nine
genes and between methylation of RASSF2A-Ex1B and nine genes.
These tumors thus appear to have a defect in their machinery regulating
methylation (supplementary Table 4 is available at Carcinogenesis
Online). The correlations between RASSF2A methylation and the clin-
icopathological features are summarized in supplementary Table 5
(available at Carcinogenesis Online).
We also detected methylation of RASSF1A in 12 of 78 (15.3%)
primary gastric cancers, where it was signiﬁcantly associated with
diffuse type (P 5 0.004), EBV (P , 0.001), absence of p53 mutation
(P 5 0.032) and the presence of CIMP-high (P , 0.001).
Discussion
Among the eight RASSF family genes and MST1/2, we found that
RASSF2A is the most frequently downregulated in gastric cancer cell
lines. Although RASSF2A has two non-coding exons, 1A and 1B,
previous studies examined the methylation of RASSF2A using meth-
ylation speciﬁc PCR, which would detect methylation downstream of
the CpG islands (22). In the present study, we showed that the major-
ity of cancer cells are methylated in the regions around both exons 1A
and 1B. In MKN28 cells, however, transcripts from exons 1A and 1B
were differentially expressed due to the low level of methylation of
exon 1B. Similarly, three primary gastric cancers showed methylation
of exon 1A but not exon 1B. All 20 primary gastric cancers that
Fig. 2. RASSF2A-mediated growth suppression and apoptosis in gastric cancer cell lines. (A and B) Suppression of cell growth by RASSF2A. Growth
suppression was evaluated by assaying geneticin-resistant colony formation. JRST and HSC44 cells were transfected with either pCDNA3.1 (control plasmid),
RASSF2A or RASSF2A-DRA and incubated in RPMI 1640 medium containing 0.6 mg/ml G418. After 14 days, the plates were stained with Giemsa solution (A),
and the colonies were counted (B). The bars indicate means ± SD of three independent experiments. (C and D) Flow cytometric analysis. (C) Representative ﬂow
cytometry after introduction of Ad-RASSF2A. The incidence of sub-G1 cells was determined 72 h after infection. (D) Quantitative analysis of sub-G1 cells.
Percentages of sub-G1 cells are shown on the y-axis. Error bars indicate standard error.
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1315showed methylation of exon 1B also showed methylation of exon 1A.
Normal tissues express both RASSF2A variants, and the functional
consequences of expressing only one remain unknown.
Methylation of RASSF2A was somewhat heterogeneous in several
celllines(e.g.HSC44andNUGC3).Inparticular,theregionaroundthe
transcriptionstartsiteinexon1AhasfewCpGsites,andmethylationof
low-density CpG islands reportedly does not mediate stable gene si-
lencing (37). Thus, other mechanisms such as aberrant histone modi-
ﬁcation may also be involved in silencing RASSF2A.T h a ti d e aw a s
conﬁrmed by our ﬁnding that, in HSC44 cells, low doses of 5-aza-dC
and TSA, which had no effect alone, acted synergistically to induce
RASSF2A. Further studies will be needed to fully characterize the way
in which histone modiﬁcation is involved in silencing RASSF2A.
The role of epigenetic inactivation of RASSF2A in gastric cancer is
not fully understood. Although alterations of K-ras/BRAF are rare in
gastric cancer, extracellular stimulation by growth factors, cytokines
and reactive oxygen species caused by H.pylori is known to activate
the Ras pathway (38,39). Likewise, genetic alterations of erbB-2
(e.g. point mutations and gene ampliﬁcation) also can lead to Ras
activation (40,41). In addition to direct activation of the Ras pathway,
inactivation of negative regulators of Ras also appears to contribute to
tumorigenesis (42). In that regard, RASSF family genes have been
identiﬁed as potential-negative regulators of Ras-induced growth that
are silenced by DNA methylation in various human neoplasias, in-
cluding gastric cancer. Furthermore, we have shown here that resto-
ration of RASSF2A expression suppresses growth of gastric cancer
cells in which RASSF2A expression had been silenced. RASSF2A’s
ability to suppress cell growth is abrogated when its RA domain is
deleted, indicating that interaction with Ras is critical to the tumor
suppressor function of RASSF2A.
The growth suppression induced by RASSF2A reﬂects an increased
incidence of apoptosis. The molecular mechanism by which RASSF2A
inducescelldeathremainsunclear,thoughweobservedthatgastriccancer
cells exhibit a round phenotype after infection with Ad-RASSF2A.
Such rounded cells were rarely detected among cells infected with
Ad-LacZ. The increase in rounded cells appears to be unrelated to
mitotic morphological changes, as accumulation of cells at G2/M
phase of the cell cycle was not detected (Figure 2C). Paxillin staining
indicated that restoration of RASSF2A expression leads to a loss of
stress ﬁbers, which would inhibit cell spreading. This is noteworthy in
Fig. 3. (A) Morphological change induced by RASSF2A. JRST cells were
infected with Ad-RASSF2A and incubated for 24 h, after which they were
stained with rhodamine-conjugated phalloidin and anti-RASSF2 antibody.
Nuclei were stained with 4#,6-diamidino-2-phenylindole. (B) Effect of
caspase inhibition on ﬂoatation-dependent cell death. After infection with
Ad-RASSF2A, the numbers of ﬂoating cells were counted. Percentages of
apoptotic cells were determined by ﬂow cytometry.
Fig. 4. Role of a NLS in determining the cellular distribution of
RASSF2A and apoptosis. (A) Cellular distribution of RASSF1 and
RASSF2A. (B) Apoptosis induced by the indicated RASSF2A mutants.
Cells were harvested, ﬁxed in methanol and stained with propidium
iodide 72 h after infection with the respective adenoviral vector.
Percentages of apoptotic cells are shown on the y-axis. Various
adenoviral vectors were infected at a multiplicity of infection of 100.
Lac-Z: Ad-LacZ; F2: Ad-RASSF2; DN: Ad-RASSF2-DN; DRA:
Ad-RASSF2-DRA; DNLS: Ad-RASSF2-DNLS.
R.Maruyama et al.
1316that mediators downstream of Ras (e.g. Rho) are involved in maintaining
the integrity of the actin cytoskeleton (43); moreover, RASSF2A sup-
presses the activation of Rho (17), which would be expected to induce
morphological changes reﬂecting a loss of stress ﬁbers. We also found
that the percentage of apoptotic cells, but not the percentage of ﬂoat-
ing cells, was reduced by a non-speciﬁc caspase inhibitor, indicating
that death occurred while the cells were ﬂoating—i.e. cell death was
not the reason the cells were ﬂoating.
Microarray screening to identify RASSF2A target genes failed to
detect induction of proapoptotic genes. Our ﬁnding that RASSF2A-
induced apoptosis was suppressed by a caspase inhibitor suggests that
RASSF2Aacts viaacaspase-dependent pathway and is consistentwith
the microarray data, in that caspase-dependent apoptosis is often in-
dependent of gene transcription (44). Apparently, RASSF2A induces
apoptosis throughmechanisms otherthan inducingproapoptotic genes.
We detected RASSF2A in both the cytoplasm and nucleus. Protein
motif analysis revealed that RASSF2A contains NLS in the region
adjacent to the RA domain, and deletion of the NLS led to accumu-
lation of RASSF2A in the cytoplasm and induction of apoptosis.
Apparently, RASSF2A’s proapoptotic activity is mediated by the cy-
toplasmic protein, and because RASSF2A interacts with Ras, which is
localized in the cytoplasm, it would seem reasonable that cytoplasmic
RASSF2A possesses the tumor suppressor activity. The role of nu-
clear RASSF2A remains to be determined.
Little is known about the downstream effectors of RASSF2A. Our
microarray analysis revealed that genes involved in inﬂammatory
responses were downregulated by RASSF2A. It was recently shown
that activation of Ras leads to upregulation of IL-8, which promotes
tumor vasculogenesis and growth (45). It also has been reported that
CXCL5, CXCL2 and CXCL3 play important roles in regulating an-
giogenic factors in various human tumors (46), and high levels of
expression of CCL20 and its receptor, CCR6, are involved in colo-
rectalcancer metastasis(47).LCN2,also known as neutrophil gelatinase-
associated lipocalin, was shown previously to be overexpressed in
a variety of tumors. LCN2 interacts with MMP9 and is involved in
epidermal growth factor-induced epithelial–mesenchymal transition
(48). Taken together, these ﬁndings suggest that RASSF2A may not
only suppress tumor growth directly but also inhibit inﬂammation and
angiogenesis through inhibition of Ras-signaling pathways.
We found that RASSF2A is frequently methylated in primary gastric
cancers that show no lymphatic invasion, venous invasion or lymph
node metastasis, less advanced stages and CIMP-high, which means
these phenotypes may simply represent the characteristics of CIMP-
highgastric cancers. Wealso found thatmethylation ofRASSF2Awas
strongly correlated with the presence of EBV. Aberrant methylation
caused by EBV is reportedly associated with induction of DNMT1
(49), which is activated by EBV via the c-Jun-NH2-kinase/activator
protein-1-signaling pathway (50). Elucidation of the mechanism by
which EBV regulates DNA methylation in gastric cancer could be
crucial for the development of new therapeutic agents.
In conclusion, we propose that RASSF2A is a keytumor suppressor
in gastric cancer that acts by suppressing cell growth and inducing
apoptosis. Our results also suggest that the antitumor activity of
RASSF2A is associated with its cytoplasmic localization and suppres-
sion of inﬂammatory cytokine expression. Thus, manipulation of the
cellular localization of RASSF2A may be an important target for
cancer therapy.
Supplementary material
Supplementary Tables 1–5, Figures 1–4 and Materials and Methods
can be found at http://carcin.oxfordjournals.org/
Fig. 5. Methylation of RASSF2A in primary gastric cancers. (A) Representative pyrogram traces for RASSF2A. Cell lines and specimens are shown below the
columns. Percentages of methylated CpG alleles are shown above the columns. (B) Expression of RASSF2A in primary gastric cancers with or without DNA
methylation. Real-time PCR was carried out using complementary DNA from primary gastric cancers. Levels of RASSF2A expression relative to those in normal
tissues are shown on the y-axis. (C) Proﬁles characterizing the methylation of RASSF1A, RASSF2Avariant 1 (RASSF2-Ex1A) and RASSF2Avariant 2 (RASSF2A-
Ex1B); mutation of K-ras or p53 and the presence of EBVin 78 gastric cancers. Positive status is indicated by a solid box. CIMP status is shown above the column.
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